Human Genome Sciences news from FierceBiotech
NewsC&L: Una Ryan leaves Avant
Avant Immunotherapeutics today announced the departure of Una Ryan, Ph.D, President and CEO, effective immediately. Watson Pharmaceuticals announced that co-founder and Chairman Allen Chao has Read more...
Rituxan fails (again) in late-stage lupus trial
Genentech and Biogen Idec were taking it on the chin this morning after researchers announced that Rituxan had failed in a later-stage trial as a therapy for lupus. The failure won't harm the Read more...
HGS, Xencor team up on antibody tech
In another display of monoclonal antibodies' appeal to drug developers, Maryland-based Humab Genome Sciences announced that it will team up with Xencor on drug development. Xencor uses its XmAb Read more...
HGS stock dives on drug safety concerns
Human Genome Sciences watched its stock take a dive this morning after an independent data monitoring committee noted lung-related side effects in patients receiving 1200-microgram injections of the Read more...
PharmAthene finds backers for research pact
PharmAthene has gained some powerful support in Washington for its plans to expand a herd of genetically modified goats used in drug research by housing the animals at a USDA facility in Maryland. Read more...
HGS, Aegera ink $315M cancer deal
Aegera Therapeutics has pocketed $20 million in a combined upfront fee and equity stake from Human Genome Sciences in exchange for the global rights (excluding Japan) to an experimental cancer drug Read more...
ALSO NOTED: Pfizer to buy CovX; Florida commits $94M to Max Planck; Affymetrix buys USB; HGS touts animal trial results for ant
> Aggressively looking to expand its role in biologics, Pfizer has struck a deal to buy CovX. No figures were given. Read more...
HGS pockets $40M for Albuferon, preps Phase III
Human Genome Sciences can bank a $40 million pay check from Novartis, its milestone for a successful Phase IIa trial of Read more...
Developers testing new therapies for lupusHuman Genome Sciences is one of several developers working on a new advance for lupus. This Wall Street Journal piece looks at the pipeline for lupus, which includes programs at Bristol-Myers Squibb, Genentech and … Read more...HGS adds positive data in extended lupus trialAn extended mid-stage trial of Human Genome Science's lymphostat for lupus has produced new positive data on the drug. The results come a year after HGS concluded that 24-week data on 449 patients did not show that lymphostat-B reduced symptoms in the disease. In June, though, HGS announced that 52 week data did demonstrate efficacy and this new data is from 76 weeks of results on 321 patients. HGS said the response rate to the drug jumped from 46 percent to 56 percent. A late-stage trial … Read more... | Press ReleasesPRESS RELEASE: Human Genome Sciences Completes Enrollment Ahead of Schedule in Second Phase 3 Albuferon(R) Trial Human Genome Sciences Completes Enrollment Ahead of Schedule in Second Phase 3 Albuferon(R) Trial ROCKVILLE, Md., Nov. 1 -- Human Genome Sciences, Inc. today announced that it has completed Read more... PRESS RELEASE: Human Genome Sciences Announces $40 Million Milestone Payment Related to Albuferon Development Human Genome Sciences Announces $40 Million Milestone Payment Related to Albuferon Development ROCKVILLE, Md., Aug. 28 -- Human Genome Sciences, Inc., today announced that it will Read more... |
Paid Research Reports
- Drug Repositioning Strategies - Serendipity by design
- eHealthInsight Series: Online Patient Recruitment Strategies - Optimizing the clinical trial process
- Pricing & Reimbursement - Seven Major Markets Update
- Innovative Clinical Trial Design and Management: Trends, success stories and impact upon R&D budgets
- The Emerging Role of Postmarketing Clinical Research: Regulatory issues, strategic drivers and overall trends